MedTrace Logo

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

NCT01649024 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-07-25

No results posted yet for this study

Summary

The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.

Conditions

  • Malignant Mesothelioma

Interventions

DRUG

Tremelimumab

Given IV

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Senese

    lead OTHER

Principal Investigators

  • Michele Maio, MD · Medical Oncology and Immunotherapy Unit, University Hospital of Siena

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-06-30
Completion
2013-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01649024 on ClinicalTrials.gov